M6A RNA methylation in biliary tract cancer: the function roles and potential therapeutic implications.

Abstract

Biliary tract cancers (BTCs) are relatively rare malignancies with a poor prognosis. For advanced BTCs, the efficacy of current chemotherapeutic approaches is limited. Consequently, there is an urgent need to deepen our understanding of the molecular mechanisms underlying BTC tumorigenesis and development for the exploration of effective targeted therapies. N6-methyladenosine (m6A), the most abundant RNA modifications in eukaryotes, is found usually dysregulated and involved in tumorigenesis, progression, and drug resistance in tumors. Numerous studies have confirmed that aberrant m6A regulators function as either oncogenes or tumor suppressors in BTCs by the reversible regulation of RNA metabolism, including splicing, export, degradation and translation. In this review, we summarized the current roles of the m6A regulators and their functional impacts on RNA fate in BTCs. The improved understanding of m6A modification in BTCs also provides a reasonable outlook for the exploration of new diagnostic strategies and efficient therapeutic targets.

• Authors: Xuesong Bai, Jianhao Huang, Yiqun Jin, Jiemin Chen, Shengnan Zhou, Liangbo Dong, Xianlin Han, Xiaodong He
• Journal: Cell death discovery (Cell Death Discov) Vol. 10 Issue 1 Pg. 83 (Feb 16 2024) ISSN: 2058-7716 [Print] United States
• PMID: 38365891 (Publication Type: Journal Article, Review)
• Copyright: © 2024. The Author(s).